Patent analysis of new target oral drugs for type 2 diabetes mellitus

WANG Lei; DING Yongbin; YANG Dawei

doi:10.6039/j.issn.1001-0408.2023.22.02

您当前的位置：

首页 >

文章列表页 >

Patent analysis of new target oral drugs for type 2 diabetes mellitus

更新时间：2023-11-25

- Patent analysis of new target oral drugs for type 2 diabetes mellitus
- ZHONGGUO YAOFANG Vol. 34, Issue 22, Pages: 2695-2700(2023)
- 作者机构：
  
  1.南京中医药大学附属南京医院（南京市第二医院）药学部，南京;210003
  2.江苏省人民医院句容分院普外科，江苏镇江　212499
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.22.02
  CLC： R95;R587.1;G255.53
- Published：30 November 2023，
  
  Received：07 April 2023，
  
  Revised：25 September 2023，
扫描看全文
王蕾,丁永斌,杨大为.2型糖尿病新靶点口服药专利分析 ^Δ[J].中国药房,2023,34(22):2695-2700.

WANG Lei,DING Yongbin,YANG Dawei.Patent analysis of new target oral drugs for type 2 diabetes mellitus[J].ZHONGGUO YAOFANG,2023,34(22):2695-2700.
王蕾,丁永斌,杨大为.2型糖尿病新靶点口服药专利分析 ^Δ[J].中国药房,2023,34(22):2695-2700. DOI： 10.6039/j.issn.1001-0408.2023.22.02.

WANG Lei,DING Yongbin,YANG Dawei.Patent analysis of new target oral drugs for type 2 diabetes mellitus[J].ZHONGGUO YAOFANG,2023,34(22):2695-2700. DOI： 10.6039/j.issn.1001-0408.2023.22.02.

摘要

目的

分析2型糖尿病新靶点口服药专利概况，为国内新型糖尿病治疗药物的研发方向和专利布局等提供参考。

方法

以HimmPat数据库中全球专利数据为基础，从专利申请量及授权量、发展趋势、地域分布、主要申请人等多个角度，对葡萄糖激酶激活剂（GKA）、蛋白酪氨酸磷酸酶1B抑制剂（PTP-1B-IN）、11β-羟基类固醇脱氢酶1抑制剂（11β-HSD1-IN）3类2型糖尿病新靶点口服药相关专利进行统计分析。结果与

结论

共检索得到GKA类专利1 649件，PTP-1B-IN类专利709件，11β-HSD1-IN类专利592件。全球主要申请主体为各大药企，其掌握了药物化合物的核心专利；其中GKA类药物的研究更成熟，专利申请量更大，企业布局更全面。国内企业、高校和科研院所在PTP-1B-IN领域具有一定的研究优势。国内企业和研究机构可以发挥传统中药资源优势，提升研究实力，可考虑从核心技术挖掘、工艺路线探索、专利布局、产学研合作、构建专利池等方面提高技术竞争力。

Abstract

OBJECTIVE

To analyze the patents of new target oral drugs for type 2 diabetes mellitus （T2DM）， and to provide references for the research and development direction and patent layout of new domestic diabetes drugs.

METHODS

Based on global patent data in the HimmPat database， from multiple perspectives such as the number of patent applications and authorization， development trend， regional distribution and main applicants， statistics and analysis were performed for the patents related to 3 types of new target oral drugs for T2DM， such as glucokinase activator （GKA）， protein tyrosine phosphatase 1B inhibitor （PTP-1B-IN）， and 11β-hydroxysteroid dehydrogenase 1 inhibitor （11β-HSD1-IN）.

RESULTS &CONCLUSIONS

A total of 1 649 patents of GKA， 709 patents of PTP-1B-IN， 592 patents of 11β-HSD1-IN were obtained， the main applicants were well-known pharmaceutical companies， which possessed the core patents of pharmaceutical compounds. The research on GKA drugs was more mature， with a larger number of patent applications and a more comprehensive enterprise layout. Domestic enterprises， universities and research institutions had advantages in the field of PTP-1B-IN. Domestic enterprises and research institutions can leverage the advantages of traditional Chinese medicine and resources to enhance their research capabilities and improve technological competitiveness through core technology exploration， the exploration of process route， patent layout， industry-university-research cooperation and the establishment of patent pool.

关键词

2型糖尿病新靶点口服药葡萄糖激酶激活剂蛋白酪氨酸磷酸酶1B抑制剂11β-羟基类固醇脱氢酶1抑制剂专利分析

Keywords

new target oral drugsglucokinase activatorprotein tyrosine phosphatase 1B inhibitor11β-hydroxysteroid dehydrogenase 1 inhibitorpatent analysis

references

中华医学会糖尿病学分会. 中国2型糖尿病防治指南：2020年版：上[J]. 中国实用内科杂志，2021，41（8）：668-695.

Chinese Diabetes Society. Guideline for the prevention and treatment of type 2 diabetes mellitus in China：2020 edition：part 1 [J]. Chin J Pract Intern Med，2021，41（8）：668-695.

刘洁. 糖尿病药物治疗的现状及进展研究[J]. 医学信息，2022，35（9）：69-72.

LIU J. Current situation and research progress of diabetic drug therapy[J]. J Med Inf，2022，35（9）：69-72.

张丽雯，阮梅花，刘加兰，等. 糖尿病领域研发态势分析[J]. 遗传，2022，44（10）：824-839.

ZHANG L W，RUAN M H，LIU J L，et al. Progress on research and development in diabetes mellitus[J]. Hereditas，2022，44（10）：824-839.

彭琴，窦芳，胡冬梅，等. 新型钠-葡萄糖协同转运蛋白2抑制剂鲁格列净治疗2型糖尿病的临床研究进展[J]. 中国药房，2020，31（19）：2422-2426.

PENG Q，DOU F，HU D M，et al. Clinical research pro-gress of a new sodium-glucose co-transporter 2 inhibitor，luseogliflozin，in the treatment of type 2 diabetes mellitus[J]. China Pharm，2020，31（19）：2422-2426.

卫晋菲，周亮，王明媚，等. 瑞格列奈对比格列美脲分别联合二甲双胍治疗2型糖尿病有效性和安全性的Meta分析[J]. 中国药房，2018，29（11）：1560-1564.

WEI J F，ZHOU L，WANG M M，et al. Meta-analysis of the effectiveness and safety of repaglinide combined with metformin versus glimepiride combined with metformin in the treatment of type 2 diabetes[J]. China Pharm，2018，29（11）：1560-1564.

冯璐璐. 国内外抗糖尿病药物专利现状分析[D]. 太原：山西医科大学，2017.

FENG L L. The analysis on the patent status of antidiabetes drugs at home and abroad[D]. Taiyuan：Shanxi Medical University，2017.

刘永贵，解学星，吴疆，等. 治疗2型糖尿病的新靶点药物研究进展[J]. 现代药物与临床，2015，30（2）：222-227.

LIU Y G，XIE X X，WU J，et al. Research progress on drugs with new targets in treatment of type 2 diabetes[J]. Drugs Clin，2015，30（2）：222-227.

袁仲，陈卓，李乾斌，等. 蛋白酪氨酸磷酸酶1B及其抑制剂的研究进展[J]. 中国药科大学学报，2018，49（1）：1-9.

YUAN Z，CHEN Z，LI Q B，et al. Advances in research of protein tyrosine phosphatase 1B and its inhibitors[J]. J China Pharm Univ，2018，49（1）：1-9.

YOON J，KIM K. Detecting signals of new technological opportunities using semantic patent analysis and outlier detection[J]. Scientometrics，2012，90（2）：445-461.

徐丹丹. 专利文本聚类分析及可视化研究[D]. 南京：南京理工大学，2009.

XU D D. Patent test clustering analysis and visualization[D]. Nanjing：Nanjing University of Science & Techno-logy，2009.

张婷，欧阳昭连. 基于专利分析及可视化的抗肿瘤药竞争态势研究[J]. 中国新药杂志，2018，27（20）：2337-2345.

ZHANG T，OUYANG Z L. The competitive situation of antitumor agents based on patent analysis and visualization[J]. Chin J N Drugs，2018，27（20）：2337-2345.

中国医学科学院药物研究所. GK和PPAR双重激动活性的嘧啶噻唑胺类衍生物：CN102786517B[P]. 2017-06-06.

Institute of Materia Medica Chinese Academy of Medical Sciences. Pyrimithiazole amine derivatives with dual agonist activity of GK and PPAR：CN102786517B[P]. 2017-06-06.

佛山市赛维斯医药科技有限公司. N-苯基金刚烷酰胺类葡萄糖激酶活化剂、制备方法及其用途：CN104610112B[P]. 2016-06-01.

Foshan Saiweisi Pharmaceutical Technology Co.，Ltd. N-phenyladamantamide type glucokinase activator，preparation method and use：CN104610112B[P]. 2016-06-01.

佛山市赛维斯医药科技有限公司. 含苯基脒结构的腈基苯噻唑羧酸酰胺类化合物、其制备及用途：CN1046101-88B[P]. 2016-07-27.

Foshan Saiweisi Pharmaceutical Technology Co.，Ltd. Nitrile based benzothiazole carboxylic acid amide compounds containing phenyl amidine structure，their preparation and use：CN104610188B[P]. 2016-07-27.

朱燕敏，王钰娇. 创新引领，源自上海：全球首创的葡萄糖激酶激活剂口服药物[J]. 张江科技评论，2022（6）：8-11.

ZHU Y M，WANG Y J. Leading by innovation，from Shanghai：the world’s first oral drug of glucokinase activator[J]. Zhangjiang Technol Rev，2022（6）：8-11.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰